ArticleExperimental hematology & oncology2025

Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients post-Allo-HSCT: a phase I trial.

Guangyu Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.